Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roger Perlmutter
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 384
- Beta
- 0.94
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -2.78
Financials
EIKN has only 5 quarterly periods on file — the charts below show the full history available.
Net Income
$-86.11MEBITDA
$-85.56MFree Cash Flow
$-69.61MEPS (diluted)
$-1.59Shares Outstanding (diluted)
54.17M+0.1%Operating Expenses
$90.55MCash & Debt
$461.72MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-324.25M | $-6.16 |
Valuation
EIKNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-25.00%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·5d ago·Negative
…vel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic p…
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029 Eikon Therapeutics NASDAQ: EIKN expects an interim analysis of its lead melanoma study in the first half of 2027 and estimates that definitive data from that trial and a lung cancer study could be available around the middle of 2029, CEO Roger Perlmutter said during a JPMorgan biotech call.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Eikon Therapeutics to Participate in Multiple Investor Conferences in November MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a G…
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
…01 Data from TeLuRide-005 at the European Society for Medical Oncology Congress MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
…ability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Sp…
View source ↗ - Newsglobenewswire.com·38d ago·Negative
…s Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metasta…
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D.
View source ↗ - Newsglobenewswire.com·88d ago·Negative
Eikon Therapeutics to Participate in Investor Conferences in September 2026 MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor co…
View source ↗ - Newsmarketbeat.com·92d ago·Neutral
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center's Vice President and Head of Clinical Development Tim Yap discussed the rationale for improving on earlier PARP inhibitor th…
View source ↗ - Newsseekingalpha.com·92d ago·Positive
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
View source ↗ - Newsglobenewswire.com·104d ago·Neutral
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D.
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-1.68 per share
Typical surprise -35.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-1.59 vs $-1.70beat
- Thu, Aug 13$-1.63 vs $-1.58miss
- Mon, May 11$-2.46 vs $-1.47miss
- Mon, Mar 30$-27.00 vs $-3.56miss
Estimates and results for EIKN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EIKN officers and directors.
- Bought
- $1.0m
- Sold
- —
1 trade
0 trades
- Column Group Iv Gp, Lpbought
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EIKN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
